- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Measuring Success in IgA Nephropathy in Clinical Practice
Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom improvement, and enhanced quality of life metrics that matter to patients in real-world settings.
EP: 1.Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations
EP: 2.Introduction to IgA Nephropathy
EP: 3.Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines
EP: 4.Diagnosing IgA Nephropathy
EP: 5.Signs and Symptoms of IgA Nephropathy
EP: 6.Challenges in Timely Identification of IgA Nephropathy
EP: 7.Clinical Impact of IgA Nephropathy and Quality of Life
EP: 8.Overview of Treatment Landscape for IgA Nephropathy: Standard of Care and KDIGO Guidelines
EP: 9.Current Treatments for IgA Nephropathy and the 4-Hit Cascade
EP: 10.Gaps in Patient Care for IgA Nephropathy
EP: 11.Emerging Anti-BAFF and Anti-APRIL Therapies
EP: 12.Emerging Therapies: Other Strategies and Important Considerations
EP: 13.The Promise of Emerging Therapies for IgA Nephropathy and Future KDIGO Guidelines
EP: 14.Sequencing and Individualizing Treatments for IgA Nephropathy
EP: 15.Measuring Success in IgA Nephropathy in Clinical Practice
EP: 16.Economic Impact of IgA Nephropathy for Patients
EP: 17.Early Diagnosis and Cost Mitigation in IgA Nephropathy
EP: 18.Cost Implications of Modulating IgA Nephropathy Disease Course
EP: 19.Patient-Reported Outcomes in the Treatment of IgA Nephropathy
EP: 20.Future Possibilities for Step Therapy in IgA Nephropathy Treatment
EP: 21.Key Managed Care Considerations for IgA Nephropathy Treatment
EP: 22.Key Economic Considerations in IgA Nephropathy: Progression to Chronic Kidney Disease
EP: 23.Closing Thoughts About IgA Nephropathy Treatment
Measuring Treatment Success in IgA Nephropathy: Beyond Clinical Trial End Points
Practical Markers of Treatment Response
Short-term Indicators (3-6 Months)
- Proteinuria reduction: Achievement of ≥ 30% reduction from baseline
- Hematuria improvement: Reduction in red blood cell counts on urinalysis
- Stabilization of estimated glomerular filtration rate (eGFR): Halting or slowing the decline in kidney function
- Resolution of nephrotic features: Improvement in edema, hypoalbuminemia, and hyperlipidemia
- Blood pressure control: Maintenance of targets with stable or reduced medication requirements
Intermediate Indicators (6-24 Months)
- Sustained proteinuria reduction: Maintenance of proteinuria < 1g/day
- eGFR trajectory: Flattening of GFR decline slope compared with pretreatment
- Reduction in gross hematuria episodes: Frequency and severity of macroscopic hematuria events
- Medication tolerance: Ability to maintain therapy without significant adverse effects
- Patient-reported outcomes: Improvement in energy levels, symptom burden, and quality of life measures
Long-term Success Metrics
- Kidney survival: Avoidance of kidney failure requiring kidney replacement therapy
- Hospitalization rates: Reduced kidney-related hospitalizations
- Medication burden: Stability or reduction in total medication requirements
- Functional status: Maintenance of work capacity and daily activities
- Cardiovascular outcomes: Reduced incidence of cardiovascular events
Practical Monitoring Approach
- Individualized surveillance: Tailoring monitoring frequency to disease severity and treatment response
- Composite assessment: Considering multiple parameters rather than single end points
- Trend analysis: Evaluating patterns over time rather than isolated measurements
- Risk reassessment: Periodic recalculation of progression risk based on current clinical status
- Patient-centered outcomes: Including measures that matter most to patients in evaluating success
Limitations of Current Approaches
- Surrogate end point reliability: Imperfect correlation between proteinuria reduction and long-term outcomes
- Biomarker availability: Limited access to specialized biomarkers (galactose-deficient IgA1, autoantibodies) in routine clinical practice
- Heterogeneous disease course: Natural fluctuations in disease activity complicating treatment effect assessment
- Follow-up duration: Need for extended monitoring to capture meaningful outcomes
Integrating these practical measures into routine care allows for more nuanced assessment of treatment success and timely intervention when therapy adjustments are needed.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
